Just call it a 'June Swoon' for Becton Dickinson and Co. (BDX), as the shares have dropped to about $69.50 from highs above $80 this spring. Even so, the business model, first discussed here on March 17, 2009 at a price of $65.66, remains preferred in these circles. Here's why: In FY2010 Becton's revenue growth should total about 5-7%, after essentially flat revenue in FY2009. Hospital spending cutbacks will hurt, but BDX should make up for that with increased government orders, lower operating costs, and moderating raw material costs. Becton's medical and diagnostic units will also likely register revenue growth at or above 5-6% in 2010; its bioscience unit will register more-modest gains.
What Happened When Alex Kenjeev Paid His Student Loan in Cash
How to Save Money at the Movie Theater
"Medical equipment giant Becton, Dickinson and Co. (
Medical equipment giant 

